Form 4: ALX Oncology Executive Granted Stock Options

Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., was granted 112,000 stock options on January 21, 2025, which vest over 48 months.

Summary

• Shelly Pinto, the SVP of Finance and CAO at ALX Oncology Holdings Inc., received 112,000 employee stock options on January 21, 2025.
• The options have an exercise price of $1.65 per share.
• These options vest in 48 equal monthly installments starting on February 21, 2025.
• The options expire on January 20, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with the company's long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 48 months is typical for such grants, designed to retain talent and incentivize long-term value creation.
• The exercise price of $1.65 is specific to ALX Oncology's stock and market conditions at the time of the grant.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns executive interests with company performance.

Key Dates

Keywords

stock options, executive compensation, insider trading, ALX Oncology, equity, vesting